NEW YORK – Troutman Pepper Locke served as intellectual property counsel for Mirum Pharmaceuticals, Inc. (Mirum), a global rare disease company with approved products and a broad pipeline of investigational medicines, in its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. For more information, see the press release.
Mirum’s acquisition expands its rare liver disease portfolio to include brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV). Brelovitug is currently being evaluated in the AZURE Phase 3 registrational program for HDV, the most severe form of viral hepatitis. The transaction introduces a fourth potential registrational readout within the next 18 months.
The Troutman Pepper Locke team that advised Mirum was led by Heather Ettinger, EA Weeks, Karl Zielaznicki, Alina Khankin, Vijaya Balakrishnan, Kasie Collins, and Tina Lin.
Troutman Pepper Locke’s Intellectual Property Practice develops and implements global protection and commercialization strategies for clients with intellectual property assets in virtually all industry areas. The firm’s forward-thinking, proactive strategies help clients mitigate risk while maximizing protection and value. With resources around the world, including an office in London, its team of attorneys, patent agents, and other professionals offer comprehensive advice on the development, acquisition, management, and monetization of intellectual property.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.